Intercept Pharmaceuticals Inc (NASDAQ:ICPT) insider Lisa Bright sold 5,000 shares of the business’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $111.42, for a total value of $557,100.00. Following the sale, the insider now owns 22,488 shares in the company, valued at approximately $2,505,612.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

ICPT traded up $0.89 during midday trading on Thursday, hitting $106.81. 367,973 shares of the company were exchanged, compared to its average volume of 656,370. The company has a market capitalization of $3.14 billion, a PE ratio of -7.43 and a beta of -1.03. Intercept Pharmaceuticals Inc has a 1-year low of $51.05 and a 1-year high of $133.74. The company has a current ratio of 5.98, a quick ratio of 5.98 and a debt-to-equity ratio of 3.83.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.65) by $0.47. The firm had revenue of $47.00 million for the quarter, compared to the consensus estimate of $48.24 million. Intercept Pharmaceuticals had a negative return on equity of 645.54% and a negative net margin of 202.93%. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.89) EPS. Equities research analysts predict that Intercept Pharmaceuticals Inc will post -10.35 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research lowered Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 28th. ValuEngine lowered Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, November 12th. Cantor Fitzgerald restated a “buy” rating and set a $170.00 price objective on shares of Intercept Pharmaceuticals in a research report on Thursday. Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, October 31st. Finally, Oppenheimer set a $100.00 price objective on Intercept Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, October 31st. Seven equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $148.25.

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wisconsin Investment Board lifted its holdings in Intercept Pharmaceuticals by 95.9% during the 2nd quarter. State of Wisconsin Investment Board now owns 22,700 shares of the biopharmaceutical company’s stock worth $1,905,000 after buying an additional 11,111 shares during the period. FMR LLC lifted its holdings in Intercept Pharmaceuticals by 17.5% during the 2nd quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock worth $372,336,000 after buying an additional 661,542 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in Intercept Pharmaceuticals by 104.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 110,805 shares of the biopharmaceutical company’s stock worth $9,298,000 after buying an additional 56,556 shares during the period. Asymmetry Capital Management L.P. acquired a new position in Intercept Pharmaceuticals during the 2nd quarter worth about $2,175,000. Finally, Rhumbline Advisers lifted its stake in shares of Intercept Pharmaceuticals by 11.5% in the 2nd quarter. Rhumbline Advisers now owns 21,153 shares of the biopharmaceutical company’s stock valued at $1,775,000 after purchasing an additional 2,181 shares during the period. 63.62% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/intercept-pharmaceuticals-inc-icpt-insider-lisa-bright-sells-5000-shares/2665790.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Further Reading: Compound Interest and Why It Matters When Investing

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.